2-hydroxy-4-methoxy-3-nitrobenzaldehyde | 53844-97-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-hydroxy-4-methoxy-3-nitrobenzaldehyde
• 英文别名: 3-Nitro-4-methoxy-salicylaldehyd
• CAS: 53844-97-6
• 化学式: C₈H₇NO₅
• mdl: MFCD08059099
• 分子量: 197.147
• InChiKey: JNAIHHSMNGGBQH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  92.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-hydroxy-4-methoxy-3-nitrobenzaldehyde 在 溴 、 溶剂黄146 作用下， 生成 5-bromo-2-hydroxy-4-methoxy-3-nitro-benzaldehyde phenylhydrazone
  参考文献：
  名称：

  Long-Term Therapy using GHB (Sodium Gamma Hydroxybutyrate) for Treatment-Resistant Chronic Alcoholics

  摘要：

  Thirty-five alcohol-dependent patients according to DSM-IV criteria who also met criteria for treatment resistance were treated with doses of gamma hydroxybutyrate (GHB) ranging between 25 and 100 mg/kg/die in an open one-year study. The results show that no patients discontinued the program during the first month of treatment. Sixty percent of these patients successfully completed the protocol; 11.4% showed complete abstinence (full responder patients); 14.3% strongly reduced their alcohol intake (partial responder patients) and 34.3% of the patients were still under treatment after one year. Forty percent of the patients were nonresponders. The retention rate under treatment of the studied sample was statistically higher than that found during the last treatment of the same subjects. No significant differences were found between full responder and partial responder patients regarding changes in clinical features, alcohol intake or social adjustment. Patients still in treatment after one year significantly differed from nonresponder patients on all the variables investigated. A six-times/daily fractionated administration of the GHB dose was the only significant predictor of the retention rate.

  DOI：

  10.1080/02791072.2001.10400478
• 作为产物：
  描述：

  2-羟基-4-甲氧基苯甲醛 在 硝酸 作用下， 以 溶剂黄146 为溶剂， 以36%的产率得到2-hydroxy-4-methoxy-5-nitrobenzaldehyde
  参考文献：
  名称：

  用于克服困难序列和抑制天冬酰胺形成的主链酰胺保护基团。

  摘要：

  主链酰胺键保护基团 2-羟基-4-甲氧基-5-硝基苄基 (Hmnb) 改善了聚集和天冬酰胺倾向肽的合成。Hmnb 的引入是自动化的，并在肽组装过程中通过将 4-甲氧基-5-硝基水杨醛添加到肽基树脂中并在树脂上还原为仲胺来进行。内部硝基苯酚酯的形成有助于受阻仲胺的酰化，该酯经历有利的O , N分子内酰基转移。这种活化的酯参与偶联并且通常在标准偶联条件下产生完全反应。Hmnb 很容易在一个制备步骤中从市售材料中获得。探索了去除酰胺保护基团的不同方法。在硝基还原为苯胺后，保护基团对酸解不稳定。展示了防止天冬酰胺形成和克服困难序列的主链保护的两个主要用途，首先是合成具有挑战性的天冬酰胺倾向测试序列，然后是经典的困难序列 ACP (65-74) 和 23 聚体均聚物的聚丙氨酸。

  DOI：

  10.1002/psc.2877

文献信息

• A backbone amide protecting group for overcoming difficult sequences and suppressing aspartimide formation
  作者：Abu‐Baker M. Abdel‐Aal、George Papageorgiou、Richard Raz、Martin Quibell、Fabienne Burlina、John Offer

  DOI：10.1002/psc.2877

  日期：2016.5

  removing the amide protecting group were explored. The protecting group is labile to acidolysis, following reduction of the nitro group to the aniline. The two main uses of backbone protection of preventing aspartimide formation and of overcoming difficult sequences are demonstrated, first with the synthesis of a challenging aspartimide‐prone test sequence and then with the classic difficult sequence ACP (65‐74)

  主链酰胺键保护基团 2-羟基-4-甲氧基-5-硝基苄基 (Hmnb) 改善了聚集和天冬酰胺倾向肽的合成。Hmnb 的引入是自动化的，并在肽组装过程中通过将 4-甲氧基-5-硝基水杨醛添加到肽基树脂中并在树脂上还原为仲胺来进行。内部硝基苯酚酯的形成有助于受阻仲胺的酰化，该酯经历有利的O , N分子内酰基转移。这种活化的酯参与偶联并且通常在标准偶联条件下产生完全反应。Hmnb 很容易在一个制备步骤中从市售材料中获得。探索了去除酰胺保护基团的不同方法。在硝基还原为苯胺后，保护基团对酸解不稳定。展示了防止天冬酰胺形成和克服困难序列的主链保护的两个主要用途，首先是合成具有挑战性的天冬酰胺倾向测试序列，然后是经典的困难序列 ACP (65-74) 和 23 聚体均聚物的聚丙氨酸。
• Long-Term Therapy using GHB (Sodium Gamma Hydroxybutyrate) for Treatment-Resistant Chronic Alcoholics
  作者：Icro Marremmani、Francesco Lamanna、Alessandro Tagliamonte

  DOI：10.1080/02791072.2001.10400478

  日期：2001.6

  Thirty-five alcohol-dependent patients according to DSM-IV criteria who also met criteria for treatment resistance were treated with doses of gamma hydroxybutyrate (GHB) ranging between 25 and 100 mg/kg/die in an open one-year study. The results show that no patients discontinued the program during the first month of treatment. Sixty percent of these patients successfully completed the protocol; 11.4% showed complete abstinence (full responder patients); 14.3% strongly reduced their alcohol intake (partial responder patients) and 34.3% of the patients were still under treatment after one year. Forty percent of the patients were nonresponders. The retention rate under treatment of the studied sample was statistically higher than that found during the last treatment of the same subjects. No significant differences were found between full responder and partial responder patients regarding changes in clinical features, alcohol intake or social adjustment. Patients still in treatment after one year significantly differed from nonresponder patients on all the variables investigated. A six-times/daily fractionated administration of the GHB dose was the only significant predictor of the retention rate.